A liquid biopsy is a blood test that finds cancerous tumors. As tumors proliferate, segments can disintegrate and spread in the bloodstream. A liquid biopsy can recognize those segments. It can detect circulating tumor cells (CTCs) which is a cancer cell from tumors that’s progressing in the bloodstream. In liquid biopsy companies, it can also detect circulating tumor DNA (ctDNA), which is a splinter from the tumor cell spreading about in the blood. DNA carries the genetic cipher or directives that regulate a cell’s deportment.
In this blog post, we will evaluate some of the contemporary in the liquid biopsy field. Also, we will delve into its fundamentals and their applications. Further, we will also take cognizance of the liquid biopsy companies that are pushing the industry ahead through inventions and contemporary product advancements. So, let’s go!
Liquid biopsy-dependent multicancer early detection (MCED) tests intend to locate numerous cancer types prematurely from a solitary blood sample. Many MCED tests are presently in progress, harnessing varied technologies to recognize unusual cfDNA attributes that are linked with cancer involving deviant DNA methylation.
Solid biopsies stay the benchmark and a patterned test in the present day’s clinical practice. In the liquid biopsy companies, they sanction the histological assessment of a tumor, offer tumor rendering, and recognize practical genetic changes to steer patient care. But solid biopsies have their restrictions. It is invasive and has particular tumors that are difficult to acquire. In these situations, a liquid biopsy assay might offer an option and help in recognizing prominent genetic changes that help in diagnosing, curing, and observing intervals of deterioration and revocation in cancer patients.
The global liquid biopsy market is poised to observe steady growth in the time to come. The market was valued at USD 11.24 billion in 2023 and is projected to grow to USD 28.52 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.9% during the forecast period from 2024 to 2032.
Here’s a look at the top liquid biopsy companies that are driving the growth of the industry:
Roche Diagnostics
Founded: 1896
Headquarters: Switzerland
Roche diagnostics advances and makes medical tests and digital instruments that offer particulars to assist healthcare experts detect the accurate treatment for patients and convey the best patient care to enhance, extend and preserve lives. Presently, Roche Diagnostics spearheads the industry in advancing diagnostic commodities for cancer, cardiac health, contagious illnesses, and women's health and diabetes handling.
Illumina Inc.
Founded: 1998
Headquarters: California, U.S.
Ilumina Inc. is an American biotechnology firm developing, making and marketing integrated systems for the survey of genetic dissimilarity and biological function. The firm offers a sequence of commodities and services that oblige sequencing, genotyping, and expression and proteomics markets and serves approximately 45 nations.
Bio-Rad Laboratories Inc.
Founded: 1952
Headquarters: California, U.S.
From its inception, Bio-Rad has persisted in offering the healthcare industry inventive and handy commodities that assist life science researchers in speeding up the discovery procedure and medical diagnostic labs in acquiring speedier and better outcomes. In the liquid biopsy companies, throughout the prevalence, they have structured durable customer relationships that assist the progress of the research and development endeavors in the initiation of contemporary products and solutions.
Myraid Genetics Inc.
Founded: 1991
Headquarters: Salt Lake, Utah
Myriad engages an aggregate of exclusive technologies that allow doctors and patients to comprehend the genetic cornerstone of human illnesses and the part that genes play in the beginning, advancement, and cure of disease. The details are utilized to attendant the advancement of contemporary commodities that examine an individual's probability for advancing illnesses later in life and recognize a patient's prospect of acknowledgment to specific drug therapy.
Genomic Health Inc.
Founded: 2000
Headquarters: California U.S.
Genomic health Inc. is a life science firm concentrated on the advancement and commodification of genomic dependent clinical laboratory services for cancer that permits physicians and patients to render customized treatment commitment. The firm is applying its first rate scientific and commercial prowess and framework to spearhead the translation of enormous amounts of genetic data into a clinically practical outcomes for treatment planning.
Precision medicines have transfigured patient care and permitted a customized perspective to selected therapeutics such as tyrosine kinase inhibitors (TKI) and immunotherapies. These therapeutics frequently rely on locating genetic changes in tumor cells and liquid biopsies provide instantaneous and effortless reach to developing tumor topography.
Attainment of client satisfaction being our motto, we at Polaris are happy to offer you multitude of reasons for why you should select us for your businesses.
Our commitment to our clients lies not only from the inception of our pre-on boarding discussions but also beyond the completion and delivery of our services.
We categorically offer custom-made/ tailored services for our syndicated research reports to provide you insights to meet the strategic requirements of your organization.
On lines of the industry best-practices, we offer our clients the finest in research and consulting services with the most reliable and accurate research findings.